Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 3/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | INSR | P06213 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | CASP9 | P55211 | 1/20 | 0.30 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19854667 | 0.90 | FFAR4 (0.31) | FFAR4 | |
| SCHEMBL19855544 | 0.89 | FFAR4 (0.33) | FFAR4CYP2C9 | |
| SCHEMBL19722063 | 0.88 | FFAR4 (0.39) | FFAR4RAB9APPARGPPARACYP2C9 | |
| SCHEMBL20313618 | 0.86 | FFAR4 (0.31) | FFAR4DGAT1CYP2C9 | |
| SCHEMBL20322612 | 0.86 | — | — | |
| SCHEMBL19855543 | 0.85 | FFAR4 (0.33) | FFAR4 | |
| SCHEMBL19853854 | 0.85 | DGAT1 (0.31) | DGAT1CYP2C9 | |
| SCHEMBL20313613 | 0.84 | CYP2C9 (0.39) | FFAR4DGAT1RAB9ACYP2C9 | |
| SCHEMBL20407537 | 0.84 | — | — | |
| SCHEMBL20313552 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3257839-B1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3257839-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | FFAR4 2665/4885DGAT1 4507/4885ESR1 560/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | FFAR4 2555/4885DGAT1 4598/4885ESR1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.